Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
3
×
amgen
3
×
biotech
3
×
boston blog main
clinical trials
life sciences
national blog main
new york blog main
new york top stories
alirocumab
boston top stories
evolocumab
inclisiran
national top stories
new york
novartis
pcsk9 inhibitors
regeneron pharmaceuticals
rna interference
the medicines company
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alopecia areata
amarin
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
axitinib
bellus health
biotech ipos
bolt biotherapeutics
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
cancer
What
drug
new
brings
cholesterol
medco
medicines
acquire
advantages
agreed
alnylam
bar
based
billion
bio
cash
company
compound
data
deal
evidence
expect
fda
gamble
heart
lasting
long
looms
lowering
market
medco’s
mover
novartis
partner
patients
payers
pharmaceuticals
physicians
plan
poised
presented
Language
unset
Current search:
amgen
×
" alnylam pharmaceuticals "
×
biotech
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms